Thinly traded nano cap VIVUS (NASDAQ:VVUS) is up 6% premarket on light volume on the news that results from a retrospective study assessing the cardiovascular safety of Qsymia (phentermine and topiramate extended-release) will be published in the February 1 issue of The Journal of Clinical Endocrinology & Metabolism.
The results, based on medical claims databases, showed that the combined risk of major adverse cardiovascular events (MACE) was not elevated in patients receiving Qsymia, or concurrently taking both phentermine and topiramate, compared to former users of these medications. There were only three MACE events over 3,245 person-years of follow-up, too few to draw definitive conclusions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.